Table 5. Antitumour activity by dose (RECIST).
Evaluable (n=23)
|
||||||
---|---|---|---|---|---|---|
Dose (mg m−2) | Number of patients | CR | PRa | s.d. | PD | NE |
300 | 3 | 0 | 0 | 2 | 0 | 1 |
500 | 3 | 0 | 2 | 0 | 0 | 0 |
600 | 3 | 0 | 0 | 1 | 0 | 0 |
700 | 6 | 0 | 1 | 3 | 1 | 0 |
800 | 3 | 0 | 1 | 0 | 1 | 1 |
900 | 4 | 0 | 0 | 2 | 0 | 1 |
1000 | 3 | 0 | 0 | 1 | 1 | 0 |
1200 | 6 | 0 | 1 | 2 | 1 | 0 |
Total | 31 | 0 | 5 | 11 | 4 | 3 |
NSCLC=non-small cell lung cancer; CR=complete response; NE=not evaluated; PD=progressive disease; PR=partial response; s.d.=stable disease.
In addition, one NSCLC patient at 500 mg m−2 had PR via WHO criteria.